Skip to content
Anuh Pharma logo

Anuh Pharma

ANUHPHR NSE
₹82.86 +1.71 (+2.11%)
P/E
18.79
View as Markdown
MCP
Close 4 Nov 2026 ₹82.86 −3.31 −3.84% 1Y
Start ₹86.17

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
14.90%
Debt to Equity
0.00
EPS (TTM)
₹4.41
Book Value
₹35.91
Market Cap
—
P/E (TTM)
18.79
P/B
2.31
ROE
10.70%
Dividend Yield
1.85%
EBITDA
₹66.10 Cr
52W High
₹99.50
52W Low
₹67.00
Day Range
₹80.00 – ₹84.36
Volume
1,15,021

Peer Comparison

Healthcare › Pharmaceuticals

Anuh Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Anuh Pharma (this company)
₹82.8618.79₹813 Cr2.311.85%10.70%14.90%₹779 Cr₹44 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.70%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

53 Average

Data confidence 100/100

Category scores

Quality
42
Weak
Returns, margins, earnings quality 22% weight
Valuation
74
Strong
Cheap vs sector & own history 24% weight
Growth
36
Poor
Sales & profit trajectory 9% weight
Financial Health
71
Strong
Solvency, leverage, coverage 9% weight
Momentum
37
Poor
Trend strength, vol-adjusted 12% weight
Ownership
55
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 24.4%

Weaknesses

1
  • Company has a low return on equity of 13.8% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2710
OscillatorsBullish072
Moving AveragesStrong Bullish208

Key readings

RSI (14)
49.75
Neutral
MACD (12,26,9)
−0.90
Bullish
SMA (50)
85.23
Bearish
SMA (200)
79.72
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+9.00%
5Y+12.31%
3Y+13.57%
1Y+16.62%
TTM+9.72%

Net profit

Net profit growth by window
10Y+4.66%
5Y+7.93%
3Y+4.43%
1Y−12.77%
TTM−2.22%

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YOutflow narrowed by ₹16 Cr
3YTurned negative
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−3.63 pp
5Y−2.39 pp
3Y−1.84 pp
1Y−1.34 pp
TTM+0.01 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹206 Cr
Mar 2018₹238 Cr
Mar 2019₹321 Cr
Mar 2020₹307 Cr
Mar 2021₹432 Cr
Mar 2022₹487 Cr
Mar 2023₹527 Cr
Mar 2024₹647 Cr
Mar 2025₹662 Cr
Mar 2026₹772 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹20.00 Cr
Mar 2018₹17.00 Cr
Mar 2019₹23.00 Cr
Mar 2020₹14.00 Cr
Mar 2021₹28.00 Cr
Mar 2022₹31.00 Cr
Mar 2023₹36.00 Cr
Mar 2024₹60.00 Cr
Mar 2025₹47.00 Cr
Mar 2026₹41.00 Cr

Quarterly Results

₹ Cr
ANUHPHR quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
161
150
172
164
138
166
160
198
186
186
197
202
194
185
Expenses
148
132
148
145
127
149
145
179
176
174
178
182
178
168
Operating Profit
14
18
24
19
11
17
15
19
10
12
19
20
16
17
OPM %
9%
12%
14%
12%
8%
10%
9%
9%
6%
6%
10%
10%
8%
9%
Other Income
3
2
4
3
4
3
1
1
3
1
2
−1
3
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
2
2
2
2
2
2
2
3
3
3
3
3
2
2
PBT
15
18
25
20
12
18
13
17
11
10
18
16
17
15
Tax %
24%
23%
24%
22%
22%
17%
22%
28%
24%
23%
25%
25%
32%
25%
Net Profit
12
14
19
15
10
15
10
12
8
8
13
12
11
11
EPS (₹)
1.17
1.38
1.91
1.53
0.95
1.5
1.03
1.24
0.83
0.76
1.34
1.17
1.14
—

Sep 2026: from the results filed on 30 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
ANUHPHR profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
284
326
206
238
321
307
432
487
527
647
662
772
779
Expenses
253
289
183
220
291
284
387
439
476
571
600
709
712
Operating Profit
31
38
23
18
30
23
45
47
52
76
62
62
67
OPM %
11%
12%
11%
8%
9%
8%
10%
10%
10%
12%
9%
8%
9%
Other Income
5
4
8
7
5
4
11
5
6
12
9
4
5
Interest
1
1
1
0
1
1
2
2
1
1
1
0.47
0
Depreciation
3
2
2
2
2
7
15
12
10
9
9
11
11
PBT
32
38
28
23
32
19
39
39
47
78
61
54
60
Tax %
31%
32%
27%
29%
28%
25%
26%
22%
24%
23%
22%
24%
—
Net Profit
22
26
20
17
23
14
28
31
36
60
47
41
44
EPS (₹)
2.19
2.57
2
1.65
2.33
1.43
2.84
3.05
3.61
5.99
4.73
4.1
4.41
Div. Payout %
27%
24%
31%
42%
29%
48%
26%
29%
28%
21%
16%
37%
—

Balance Sheet

₹ Cr
ANUHPHR balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
13
13
13
13
13
25
25
25
25
25
50
Reserves
97
107
128
137
152
150
166
189
216
266
301
302
Borrowings
0
2
0
2
4
45
14
4
1
3
11
0
Other Liabilities
67
71
48
57
71
119
128
129
163
152
170
205
Total Liabilities
168
193
189
209
240
326
333
347
405
446
507
557
Fixed Assets
9
18
17
17
21
84
71
61
53
49
58
57
CWIP
0
0
0
6
34
0
0
0
0
0
0
0
Investments
43
43
70
66
39
80
31
43
91
97
106
84
Other Assets
116
131
101
120
147
163
230
243
261
300
342
416
Total Assets
168
193
189
209
240
326
333
347
405
446
507
557

Cash Flow

₹ Cr
ANUHPHR cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
16
26
2
7
49
−19
29
54
13
37
−3
Investing
−12
−5
−20
2
3
−77
52
−8
−43
1
−20
18
Financing
−8
−9
−4
−5
−7
22
−33
−19
−12
−9
−5
−26
Net Cash Flow
−1
2
2
−1
3
−5
0
2
−2
5
12
−12
Free Cash Flow
18
6
25
−5
−22
13
−25
27
52
8
17
−11
CFO/EBITDA
96
78
149
49
56
232
−20
80
130
42
78
16

Ratios

ANUHPHR financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
84
100
109
85
96
90
102
118
107
119
113
Inventory Days
27
35
72
64
64
98
90
77
66
57
54
90
Days Payable
79
77
102
105
89
166
133
117
139
105
115
114
Cash Conversion Cycle
36
42
70
68
61
28
48
62
46
58
59
89
Working Capital Days
43
48
79
80
65
−10
57
68
61
69
68
92
ROCE %
33%
35%
19%
14%
19%
10%
16%
18%
19%
26%
17%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Anuh Pharma insights

63 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 71.80%
  • Public 23.17%
  • Others 4.92%
  • FIIs 0.11%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY27 concall · Aug 2026
    PPT
  • Concall · May 2026
    PPT
  • Q3 FY26 concall · Feb 2026
    PPT
  • Concall · Nov 2025
    PPT
  • Q1 FY26 concall · Aug 2025
    PPT

Frequently Asked Questions about Anuh Pharma

What does Anuh Pharma Ltd do?
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals
Where is Anuh Pharma Ltd (ANUHPHR) listed?
Anuh Pharma Ltd trades as ANUHPHR on the NSE and under code 506260 on the BSE.
Which sector does Anuh Pharma Ltd belong to?
Anuh Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Anuh Pharma Ltd?
Anuh Pharma Ltd trades at a PE ratio of 18.79 as of 4 Nov 2026, on earnings per share of ₹4.41, against a book value of ₹35.91 per share.
What is the 52-week high and low of Anuh Pharma Ltd?
Over the last 52 weeks Anuh Pharma Ltd has traded between ₹67 and ₹99.5 as of 4 Nov 2026.
Does Anuh Pharma Ltd pay dividends?
Anuh Pharma Ltd has a dividend yield of 1.85%.
What is the Return on Equity (ROE) of Anuh Pharma Ltd?
Anuh Pharma Ltd reported a return on equity of 10.70%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals

Website anuhpharma.com
CEO Mr. Ritesh Bipin Shah MBA
Employees 295
Listed 2 Jan 2008
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ANUHPHR.md for Anuh Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month